指南与共识肝病

代谢功能障碍相关脂肪性肝病的新定义:国际专家共识声明

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
指南 / 共识 · J Hepatol · 2020-04-08

来自22个国家的国际专家小组提出代谢功能障碍相关脂肪性肝病(MAFLD)的新诊断定义,该定义基于肝脂肪变证据加上超重/肥胖、2型糖尿病或代谢功能障碍三者之一,不依赖排除其他肝病。共识还建议超越单纯脂肪性肝炎与非脂肪性肝炎的二分法进行疾病评估和严重程度分层,并提出MAFLD相关肝硬化的定义标准及区分诊断标准与研究纳入标准。

要点

  • MAFLD诊断采用阳性标准:肝脂肪变加超重/肥胖、2型糖尿病或代谢功能障碍之一。
  • 新定义不要求排除其他慢性肝病,包括过量饮酒。
  • 建议疾病评估和严重程度分层超越脂肪性肝炎与非脂肪性肝炎的二分法。

核心结论

  • 国际专家小组提出MAFLD的新定义,基于肝脂肪变证据加上超重/肥胖、2型糖尿病或代谢功能障碍三者之一,不依赖排除其他肝病。

研究设计与样本

  • 来自22个国家的国际专家小组共识声明。

主要发现

  • 新定义基于肝脂肪变证据加上超重/肥胖、2型糖尿病或代谢功能障碍三者之一。
  • 建议疾病评估和严重程度分层应超越单纯的脂肪性肝炎与非脂肪性肝炎二分法。
  • 提出MAFLD相关肝硬化的定义标准及考虑其他脂肪性肝病原因的概念框架。
  • 澄清诊断标准与研究/临床试验纳入标准的区别。

关键数值与推荐

  • MAFLD诊断标准:肝脂肪变证据加上超重/肥胖、2型糖尿病或代谢功能障碍三者之一。

临床怎么用

  • 共识统一术语有助于ICD编码,增强临床实践和临床试验的合法性,改善临床诊疗并推动肝病研究领域发展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The exclusion of other chronic liver diseases including "excess" alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, "positive criteria" to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis vs. non-steatohepatitis. The group also suggests a set of criteria to define MAFLD-associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020. PMID: 32278004. doi:10.1016/j.jhep.2020.03.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。